Wong, Founder and CEO of HCW Biologics, stated, "In the third quarter 2024, the Company expanded our product portfolio and ...

On track to file New Drug Applications (NDAs) for NRX-100 (IV Ketamine) in treating suicidal ideation in depression, including bipolar depression and NRX-101 (Oral D-Cycloserine/Lurasidone) for ...

Core focus on obesity includes exploratory co-administration BMT-801 study and two novel development drug candidatesPhase 2 BMT-801 clinical study with MC4R agonist bremelanotide plus GLP-1/GIP dual ...

Phase 2b clinical trial of GH001 in patients with treatment-resistant depression completed enrolment of the double-blind phase in Q3 2024Phase 1 ...

For the pandemic flu candidate, toxicology studies are now underway and we are actively discussing funding ... We plan to ...

Clinical Cancer Research publishes articles that focus on innovative clinical and translational research bridging the laboratory and the clinic. Topics include targeted therapies; mechanisms of drug ...

PulseSight Therapeutics SAS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead ...

with clinical trial initiation expected in 2025. In vivo assessment of anti-tumor activity was performed with a murine surrogate of BDC-4182 using xenograft and syngeneic tumor models with different ...

By Kodjo Adams Accra, Nov.6, GNA- Herbal medicine practitioners have been urged to collaborate with research scientists to ensure the rigorous scientific validation of herbal medicines, which ...

AS, an ophthalmology biotech company developing disruptive non-viral vectorized therapies with minimally-invasive delivery technology, has presented new data on its lead program PST-611, a DNA plasmid ...

Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response at the U.S. Department of Health and Human Services, as part of ...